阿托伐他汀对急性心肌梗死冠脉介入治疗术后的疗效及再狭窄的影响

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (2): 199-203.

阿托伐他汀对急性心肌梗死冠脉介入治疗术后的疗效及再狭窄的影响

邓少雄¹, 郑渊¹, 郭南鸥²

¹福建省泉州医学高等专科学校内科教研室,²福建医科大学附属泉州市第一医院心内科,泉州 362000,福建

收稿日期:2009-09-02 修回日期:2010-01-06 出版日期:2010-02-26 发布日期:2020-09-18
作者简介:邓少雄,男,医学学士,副教授,主要研究冠心病的基础与临床。Tel: 0595-22835346 E-mail: drdengsx@126.com

Influence of atorvastatin on the curative effect and restenosis in patients with acute myocardial infarction for postoperative percutaneous coronary intervention

DENG Shao-xiong¹, ZHENG Yuan¹, GUO Nan-ou²

¹ Medical Department of Quanzhou Medical College, ² Department of Heart Internal Medicine, Affiliated the First Hospital of Quanzhou,Fujian Medical University, Quanzhou 362000,Fujian,China

Received:2009-09-02 Revised:2010-01-06 Online:2010-02-26 Published:2020-09-18

摘要/Abstract

摘要： 目的:观察不同剂量阿托伐他汀对急性心肌梗死(acute myocardial infarction,AMI) 冠脉介入治疗(percutaneous coronary intervention,PCI)术后的疗效及再狭窄的影响。方法:选择急性心肌梗死PCI术后的患者162例,按不同剂量阿托伐他汀分为A 组 20 mg/d、B组 40 mg/d,每组调脂治疗共12个月。分别于PCI术前及PCI术后6个月末、12个月末测定血脂水平、血清C反应蛋白(CRP)、IL-6、NO、降钙素基因相关肽(CGRP)、血浆内皮素-1(ET-1)、肱动脉舒张内径变化率(D%)、肝肾功能及心肌酶水平;主要观察阿托伐他汀疗效、不良反应和心脏不良事件。结果:治疗后B组的TC、低密度脂蛋白胆固醇(LDL-C)、CRP、IL-6、ET-1降低,高密度脂蛋白胆固醇(HDL-C)、NO、CGRP、ΔD%升高与A组PCI术后同期比较,差异有统计学意义(P＜0.05),并且无严重不良反应。B组降低PCI术后再狭窄的发生率与A组比较,差异也有统计学意义(P＜0.05)。结论:大剂量阿托伐他汀的抗炎作用及改善血管内皮功能明显,能显著降低PCI术后再狭窄的发生率。

关键词: 阿托伐他汀, 心肌梗死, 冠脉介入治疗, 再狭窄

Abstract: AIM: To investigate the influence of different dose atorvastatin on the curative effect and restenosis in patients with acute myocardial infarction for postoperative percutaneous coronary intervention (PCI). METHODS: 162 patients with acute myocardial infarction for postoperative PCI were divided into Group A(atorvastatin 20 mg/d group) and Group B(atorvastatin 40 mg/d group), both of which were treated with atorvastatin for 12 months. Serum lipid, CRP, IL-6, NO, CGRP, ET-1, D%, liver function,renal function and CK were measured before PCI, 6 months and 12 months after PCI.In addition,the curative effects of atorvastatin,adverse cardiovascular outcomes and side effect of atorvastatin were observed. RESULTS: Compared with the Group A, the TC, LDL-C, CRP, IL-6, ET-1 were significantly reduced and the HDL-C, NO, CGRP, D% were improved in Group B after treatment(P<0.05), and there was no statistical difference(P＜0.05) with no severe side effect. In addition,the morbidity of restenosis after PCI in Group B was decreased, and there was no statistical difference(P＜0.05). CONCLUSION: High dose atorvastatin have a significantly anti-inflammatory effect and endothelial function improvement, decreasing significantly the morbidity of restenosis after PCI.

Key words: Atorvastatin, Myocardial infarction, Percutaneous coronary intervention, Restenosis

中图分类号:

R587.106

邓少雄, 郑渊, 郭南鸥. 阿托伐他汀对急性心肌梗死冠脉介入治疗术后的疗效及再狭窄的影响[J]. 中国临床药理学与治疗学, 2010, 15(2): 199-203.

DENG Shao-xiong, ZHENG Yuan, GUO Nan-ou. Influence of atorvastatin on the curative effect and restenosis in patients with acute myocardial infarction for postoperative percutaneous coronary intervention[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(2): 199-203.

[1]	郝潇, 赵美, 王文静, 张飞飞, 刘惠良, 党懿, 李树仁, 齐晓勇. 钠-葡萄糖共转运体2抑制剂在急性心肌梗死应用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 824-831.
[2]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[3]	钱锦, 王峰岩. 老年急性心肌梗死患者PCI术后血清NT-proBNP水平的影响因素并分析其对近期预后的影响[J]. 中国临床药理学与治疗学, 2023, 28(6): 658-665.
[4]	梁美芳, 陈庆状, 杨沛群, 王勇. 基于真实世界的阿托伐他汀仿制药和原研药防治缺血性脑卒中/短暂性脑缺血发作的有效性和安全性比较[J]. 中国临床药理学与治疗学, 2022, 27(7): 785-792.
[5]	陈曦, 李拥军. 活血类中成药在心肌梗死后心脏修复中的作用[J]. 中国临床药理学与治疗学, 2022, 27(6): 680-688.
[6]	杨永康, 李静, 饶廷彩, 张骏艳. 金丝桃苷通过调节自噬水平减轻心肌梗死小鼠心脏及胸主动脉的损伤[J]. 中国临床药理学与治疗学, 2021, 26(6): 601-608.
[7]	赵玮, 吴悠扬, 林丛, 黄时伟, 陈皓, 姜文兵. 紫檀芪对急性心肌梗死大鼠心肌功能、心肌纤维化和炎症反应的作用及对Notch1/eIF3a信号通路的影响[J]. 中国临床药理学与治疗学, 2020, 25(5): 498-504.
[8]	谢祥妹，黄志红，刘小菊，薛冰，蓝保珠. 叶酸片联合阿托伐他汀治疗对H型高血压患者同型半胱氨酸及颈动脉粥样硬化的影响[J]. 中国临床药理学与治疗学, 2020, 25(4): 455-459.
[9]	傅小媚，霍然，邓赛，林潮金，范景皓，王萍，李松沛，秦爱萍，邹明辉，余细勇. 脂多糖刺激的骨髓间充质干细胞来源外泌体改善小鼠心肌梗死后炎症和纤维化[J]. 中国临床药理学与治疗学, 2019, 24(8): 841-851.
[10]	黄立佳，黄杨，孔劲松，郑鑫，宫小康，阮建伟，王海宝. 阿托伐他汀钙经STAT1-caspase-3信号轴抑制膝骨关节炎大鼠关节软骨退变的研究[J]. 中国临床药理学与治疗学, 2018, 23(7): 743-748.
[11]	韦喻镪. 利拉鲁肽对急性心肌梗死PCI术后心肌的保护作用[J]. 中国临床药理学与治疗学, 2018, 23(2): 184-188.
[12]	杨亚楠，陈莉梅，陶春蕾. 阿托伐他汀钙片在中国健康受试者的生物等效性试验[J]. 中国临床药理学与治疗学, 2018, 23(11): 1258-1264.
[13]	姜海，姜国志，陈钟，李振江. 姜黄提取物联合阿托伐他汀钙对高脂血症小鼠降血脂作用的研究[J]. 中国临床药理学与治疗学, 2017, 22(1): 48-51.
[14]	浦春, 陶青松，朱翔，秦明明，武其文，冯钢. 三种心肌损伤标志物在急性心肌梗死早期诊断中的应用价值[J]. 中国临床药理学与治疗学, 2017, 22(1): 82-86.
[15]	张莹，王安才，王新，王德国，邢文. 阿托伐他汀对腹主动脉缩窄性高血压大鼠心肌组织蛋白酶S、K的影响[J]. 中国临床药理学与治疗学, 2016, 21(9): 968-972.